UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
- Study Identifier: 831302
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com